GammaDelta Therapeutics expands management team

4-May-2017

Paolo Paoletti leads as Chief Executive Officer

GammaDelta Therapeutics, an emerging biotech company developing immunotherapies for cancer and other diseases, has expanded its leadership team with the appointments of Paolo Paoletti as Chief Executive Officer and Natalie Mount as Chief Scientific Officer.

Paoletti has more than 20 years of clinical, commercial and leadership experience in the pharmaceutical sector. He was formerly the first appointed President of GSK Oncology, where he was responsible for the overall oncology business within the firm.

He oversaw all research and development activities from early discovery through clinical development, launch and life cycle management, covering a spectrum of drug modalities. Most recently, Paoletti was Chief Executive Officer of Kesios Therapeutics.

Natalie Mount joins GammaDelta from the Cell and Gene Therapy Catapult where she was Chief Clinical Officer, responsible for the translational, regulatory and clinical development activities.

Prior to that, she spent 16 years at Pfizer leading development activities across various therapeutic areas, including cell based therapies in the Regenerative Medicine Unit.

Other appointments

Dayle Hogg has joined as Chief Operating Officer. He most recently worked at Kesios Therapeutics as Chief Operating Officer following his role as an Investment Manager at Touchstone Innovations.

Sign up for your free email newsletter

Raj Mehta, had become Director of Intellectual Property, Alliance Management and Business Development. This follows his role as Commercial Founder and interim CEO of GammaDelta, where he was involved in the formation of the company, alongside his role as a Business Development Executive at Cancer Research Technology.

Companies